1 / 24

1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0

1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons) Sx in 79 departments, RT in mainly 6 centres. Overgaard et al. NEJM 1997 337:949.

Download Presentation

1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons) Sx in 79 departments, RT in mainly 6 centres Overgaard et al. NEJM 1997 337:949 These Power Point presentations are free to download only for academic purposes, with due acknowledgements to authors and this website.

  2. 64% 56% 318 patients, 1979 – 1986, premenopausal, node +, any T, M0 MRM + CMF +/- 37.5Gy/16fx RT (photons) Sx by ‘specialists’, CT & RT in one centre 54% 41% Ragaz et al. NEJM 1997 337:956

  3. 1460 patients, 1982 – 1990, postmenopausal, node +, any T, M0 MRM + Tamoxifen +/- 50Gy/25fx RT (electrons + photons) Sx in 79 departments, RT in mainly 6 centres Overgaard et al. 1999, 353:1641

  4. Vascular deaths: Proportional excess ratio=1.3, absolute rates 3 fold greater

  5. What were the problems with the EBCT review? • Diverse surgical treatments (BCT, MRM, RM, simple mastectomy) • Systemic therapies (including trials with no systemic therapies) • Radiotherapy doses, areas treated, kind of radiation, doses to the heart

  6. Any recurrence

  7. Loco-regional recurrence

  8. Survival

  9. Loco-regional failure (LRF) is  25% for >4 nodes; T >5 cm; < 6 nodes at axillary dissection; patient younger than 40 • PMRT reduces this risk to 6 – 8% (absolute benefit of 17-19 women for each 100 treated) • In the subgroup of 1-3 nodes, LRF is 13%; PMRT reduces this to 3-4% (absolute benefit of 9-10 women for every 100 treated) • For a LRF reduction of 20%, cancer specific survival improves by 4-5% • A North-American trial on PMRT for 1-3 nodes was closed due to insufficient interest!!!

  10. Objective: Information and recommendations on PMRT Outcomes: LRC, DFS, OS, toxicities Source of evidence: Review of meta analysis, consensus statements1966 – 2002 + RCTs between 1995 – 2002 (to supplement ASCO guidelines)

  11. Recommendations -1 • PMRT: Tumor > 5cm, invasion of skin, pectoral muscle or chest wall • PMRT: 4 or more positive nodes • PMRT ??: 1-3 positive nodes Danish 82b: T > 5cm : LR failure 12%(RT) vs 42% (no RT) Danish 82c: T > 5cm : LR Failure 10%(RT) vs 34% (no RT) Deep fascia : LR Failure 6%(RT) vs 45% (no RT) Skin : LR Failure 8%(RT) vs 34% (no RT)

  12. LRF and OS by nodal status

  13. Recommendations -2 • PMRT not recommended in tumors less than 5 cm and negative axilla Risk of local recurrence is 9.2% without and 2.7% with PMRT (EBCTCG)

  14. Recommendations -3 • Age, grade, LVI, hormone receptor status, number of nodes removed, extracapsular spread may affect LRC but indications unclear

  15. Recommendations -4 • PMRT should encompass chest wall, supraclavicular, infraclavicular area and axillary apex • After complete dissection of the axilla (level I and II) avoid radiating the axilla • Definite recommendations to include IMC (Investigational in an EORTC trial) • Use modern techniques, avoid heart and lungs • Acute effects: skin reactions. Late effects-cardiac(relative hazard 3.2 times) /pulmonary (3%) /rib fractures/brachial plexopathy are rare

  16. ISODOSE DISTRIBUTION Prescription Isodose (100%) 1cm off axis

  17. Recommendations -5 • Sequencing of PMRT and systemic therapy unclear. Do not administer concomitantly with anthracyclines or taxanes

  18. Delay in RT (for giving CT before RT) reduces Local controlMeta-Analysis of 1927 breast cancer patients (mostly BCT)

  19. Univ. Med Centre, Utrecht, The Netherlands, Fiets et al 154 patients (BCT – 107, MRM - 47) ref during 1996-99 RT 50Gy / 25# (BCT: 16Gy boost); Nodal RT in 71 patients Chemo if indicated; CMF or AC on Med Oncologist’s discretion RT alone (n=61) RT + CMF (n=51) RT + AC (n=42) Prospective detailed evaluation of acute Toxicities Before, During & After RT (up to 6 months)

  20. RT alone (n=61) RT + AC (n=42 RT + CMF (n=51) Incidence of SEVERE (Grade 2- 4)Acute Toxicities Moist Desquamation 21% 41% 70% Dysphagia 5% 18% 36% Dyspnoea 17% 43% 43% R. Pneumonitis 2% 4% 5% (NS) Malaise 40% 61% 62% Anorexia 2% 20% 41% Fever 0% 10% 11%

More Related